12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective is to investigate the efficacy, safety and pharmacokinetics of three different
doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes
mellitus with insufficient glycemic control. In addition an open-label metformin arm will be
assessed